List of publications Maureen Rutten-van Mölken (updated July 22, 1010)

Size: px
Start display at page:

Download "List of publications Maureen Rutten-van Mölken (updated July 22, 1010)"

Transcription

1 List of publications Maureen Rutten-van Mölken (updated July 22, 1010) Submitted Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MPMH, Beeh KM, Rabe KF, Fabbri LM, for the POET-COPD investigators. Tiotropium versus salmeterol for the prevention of COPD exacerbations (submitted) Petrillo J, van Nooten F, Jones P, Rutten-van Mölken MPMH, Kline Leidy N. Utility Estimation in Chronic Obstructive Pulmonary Disease (COPD): A Preference for Change? (submitted) Tsiachristas A, Hipple-Walters B, Lemmens K, Nieboer A, Rutten-van Mölken M. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers (submitted) Hoogendoorn M, Feenstra T, Hoogenveen RT, Al M, Rutten-van Mölken MPMH. The association between lung function and exacerbation frequency in patients with chronic obstructive pulmonary disease, results from a systemic review. (Submitted) De Korte D, Van Schayck CP, Van Spiegel P, Kaptein A, Sachs A, Rutten-van Mölken MPMH, Chavannes N, Tromp Beelen T, Bes R, Allard R. Kansen voor Nederlandse zorgprofessionals in de begeleiding van stoppen met roken Een onderzoek naar knelpunten in wetenschappelijke kennis en tabaksverslavingszorg in Nederland (submitted) Goossens LMA, Nivens MC, Monz BU, Rutten-van Mölken MPMH. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? (submitted) Lemmens KMM, Nieboer AP, Rutten-Van Mölken MPMH, Van Schayck CP, Spreeuwenberg C, Asin JD, Huijsman R. A Multi-Site Comparison to Evaluate the Effectiveness of Disease-Management Programmes using a Bottom-Up Approach. (submitted) Goossens LMA, Rutten-van Mölken MPMH. Do treatment guidelines match with current cost-effectiveness evidence? The case of asthma and COPD in Dutch guidelines. (submitted) Oppe M, Al M. Rutten-van Mölken MPMH. Comparing methods of data synthesis. Updating parameters of an existing probabilistic cost-effectiveness model. (submitted) Peer reviewed journals Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MPMH, Brekke PH, Vestbo J, Feenstra T. Case-fatality of COPD exacerbations: a meta-analysis and statistical modeling approach. Eur Respir J (in press) Hoogendoorn M, Feenstra T, Rutten-van Mölken MPMH. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease. Thorax (in press) 1

2 Vemer P, Rutten-van Mölken MPMH. Largely Ignored: The impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ (in press) Hoogendoorn M, Van Wetering CR, Schols AM, Rutten-van Mölken MPMH. Is INTERdisicplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010; 35: Van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Mölken MPMH, Schols AM. Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010; 65: Van Wetering CR, Hoogendoorn M, Broekhuizen R, Geraerts G, De Munck DRAJ, Rutten-van Mölken MPMH, Schols AM. Efficacy and costs of nutritional rehabilitation in patients with COPD in a community based setting: a randomized controlled trial. Journal of the American Medical Directors Association 2010 (in press) Gani R, Griffin J, Kelly S, Rutten-van Mölken MPMH. Economic analysis comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal 2010; 19(1): Vemer P, Rutten-van Mölken MPMH. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010; 13 (2): Vemer P, Rutten-van Mölken MPMH, Kaper J, Hoogenveen RT, Van Schayck CP, Feenstra TL. If you stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation therapies in the Netherlands. Addiction 2010; 105(6): Hakkaart-van Roijen L, Swan Tan S, Goossens L, Schawo S, Brouwer W, Rutten-van Mölken M, Rutten F. Doelmatigheid in praktijkrichtlijnen voor medicijnen: resultaten van een quick scan. Nederlands Tijdschrift voor Geneeskunde 2010; 88 (4): Lemmens K, Nieboer A, Rutten-Van Mölken MPMH, Van Schayck CP, Asin J, Dirven J, Huijsman R. Application of a theoretical model to evaluate COPD disease management. BMC Health Services Research 2010; 10: 81 Rutten-van Mölken MPMH. Raising the awareness: projecting the future burden of COPD with the BOLD model. Eur Respir J 2009; 34: Rutten-van Mölken MPMH, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27: Hoogendoorn M, Van Wetering CR, Schols AM, Rutten-van Mölken MPMH. Self-report versus care provider registration of health care utilization: impact on cost and cost-utility. Int J Technol Assess Health Care 2009; 25: Beeh K-M, Hederer B, Glaab T, Müller A, Rutten-van Mölken M, Kesten S, Vogelmeier C, Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of COPD 2009; 4: Goossens LMA, Riemersma RA, Postma DS, Van der Molen T, Rutten-van Mölken 2

3 MPMH. Is SMART wise in general practice? An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Adv Ther 2009; 26: Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPMH. Expected value of perfect information: an example of reducing decision uncertainty by conducting additional research. Value in Health 2008; 11(7): Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM; CAMERA Study GroupMembers listed in the Appendix. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf Apr;17(4): Van Wetering CR, Van Nooten FE, Mol SJM, Hoogendoorn M, Rutten-van Mölken MPMH, Schols AM. Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial. Int J Chron Obstruct Pulmon Dis. 2008;3(3): Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MPMH, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF on behalf of the Americal Thoracic Society/Eurpean Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD Pharmacological Trials: from lung function to biomarkers. Eur Respir J 2008; 31: Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008; 24(1): Rutten-van Mölken MPMH, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost-effectiveness of Tiotropium, Salmeterol and Ipratropium for the treatment of COPD in Spain. Eur J Health Econ 2007; 8: Rutten-van Mölken MPMH, Van Nooten FE, Lindemann M, Caeser M. Calverley PMA. A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease (COPD). PharmacoEconomics 2007; 25(8): Poley MJ, Edelenbos KI, Mosseveld M, Van Wijk MAM, De Bakker DH, Van der Lei J, Rutten-van Mölken MPMH. Cost consequences of implementing an electronic decision support system for ordering laboratory tests in primary care: evidence from a controlled prospective study in The Netherlands. Clin Chem 2007; 53(2): Rutten-van Mölken MPMH, Lee TA. Economic Modelling in COPD. Proceedings of the American Thoracic Society 2006; Rutten-van Mölken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does Quality of Life of COPD patients as measured by the generic EQ-5D differentiate between COPD severity stages? Chest 2006; 130: Hoogendoorn-Lips M, Feenstra T, Schermer T, Hesselink A, Rutten-van Mölken M. 3

4 Severity distribution of physician diagnosed chronic obstructive pulmonary disease. Respiratory Medicine 2006; 100: Hoogendoorn-Lips M, Feenstra TL, Rutten-van Mölken MPMH. Toekomstprojecties van het zorggebruik en de kosten van astma en COPD in Nederland. NTvG (22): Hoogendoorn-Lips M, Rutten-van Mölken MPMH, Feenstra TL. Letter to the Editor. Eur Respir J 2006; 27(1): Korthals-de Bos IBC, Gerritsen AAM, Van Tulder MW, Rutten van Mölken MPMH, Ader HJ, De Vet HCW, Bouter LM. Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. BMC Musculoskelet Disord Nov 16; 7: 86. Hoogendoorn-Lips M, Rutten-van Mölken MPMH, Hoogenveen RT, Van Genugten MLL, Buist AS, Wouters EFM, Feenstra TL. A dynamic population model of disease progression in chronic obstructive pulmonary disease. Eur Respir J 2005; 26: Decramer M, Rutten-van Mölken MPMH, Dekhuijzen R, Troosters T, Van Herwaarden C, Pellegrino R, Van Schayck O, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-Acetyl-cysteine on outcomes in COPD. The bronchitis randomized on NAC cost-utility study (BRONCUS). Lancet 2005; 265: Oostenbrink JB, Rutten-van Mölken MPMH, Monz BU, FitzGerarld JM. Probabilistic Markov model to asses the cost-effectiveness of tiotropium in COPD patients in different countries. Value in Health 2005; 8: Feenstra TL, Hamberg-Van Reenen HH, Hoogenveen RT, Rutten-van Mölken MPMH. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modelling study. Value in Health 2005; 8: Decramer M, Gosselink R, Rutten-van Mölken M,.Buffels J, Van Schayck O, Gevenois P-A, Pellegrino R, Derom E, De Backer W. Assessment of progression of COPD: report of a workshop held in Leuven, March Thorax 2005; 60: Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ. Van Noord JA, Vincken W. One-year cost-effectiveness analysis of tiotropium compared to ipratropium for the treatment of COPD. Eur Respir J 2004: 23: Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors of high cost exacerbations. Respiratory Medicine 2004: 98: Korthals-de Bos IBC, Smidt N, Van Tulder MW, Rutten van Mölken MPMH, Ader HJ, Van der Windt DAWM, Assendelft WJJ, Bouter LM. Cost-effectiveness of interventions for lateral epicondylitis: results from a randomized controlled trial in primary care. PharmacoEconomics 2004; 22(3): Bueving HJ, Van der Wouden JC, Raat H, Bernsen RMD, De Jongste JC, Van Suijlekom- Smit LWA, Osterhaus ADME, Rimmelzwaan GF, Rutten-van Mölken MPMH, Thomas S,. Influenza vaccination in asthmatic children: effects on quality of life and symptoms. Eur Respir J 2004; 24:

5 Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Influenza vaccination in asthmatic children: randomised double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004; 169: Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Does influenza vaccination exacerbate asthma in children? Vaccine 2004: 23: Bueving H, Bernsen R, De Jongste J, Van Suijlekom-Smit L, Rimmelzwaan G, Osterhaus A, Rutten-van Mölken M, Thomas S, Van der Wouden J. Huisarts en Wetenschap 2004: 47(11): Oostenbrink JB, Al MJ, Rutten-van Mölken MPMH, Methods to analyse cost data of patients who withdraw in a clinical trial setting. PharmacoEconomics 2003; 21(15): Korthals-de Bos IBC, Hoving JL, Van Tulder MW, Rutten-van Mölken MPMH, Ader HJ, De Vet HCW, Koes BW, Vondeling H, Bouter LM. Cost-effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ 2003; 326: Boonen A, Van der Heijde D, Landewe R, Guillemin F, Rutten-van Mölken MPMH, Dougados M, Mielants H, De Vlam K, Van der Tempel H, Boesen S, Spoorenberg A, Schouten H, Van der Linden Sj. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62: Boonen A, Van der Heijde D, Landewe R, Guillemin F, Spoorenberg A, Schouten H, Rutten-van Mölken MPMH, Dougados M, Mielants H, De Vlam K, Van der Tempel H, Van der Linden Sj. Costs of ankylosing spondylitis in three European countries: the patient s perspective. Ann Rheum Dis 2003; 62: Feenstra TL, Rutten-van Mölken MPMH, Jager JC, Van Essen-Zandvliet EEM. The cost effectiveness of guideline advice for children with asthma: a literature review. Pediatric Pulmonology 2002; 34: Boonen A, Van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Mölken MPMH, Guillemin F, Dougados M, Mielants H, De Vlam K, Van der Tempel H, Van der Linden Sj. Work-status and productivity costs due to ankylosing spondylitits: A comparison among three European countries. Ann Rheum Dis 2002; 61: Van Tubergen A, Boonen A, Landewe R, Rutten-van Mölken MPMH, Van der Heijde D, Hidding A, Van der Linden Sj. Cost-effectivenesss of combined spa-exercise therapy in ankylosing spondylitits: a randomised controlled trial. Arthritis Rheumatism (Arthritis Care Res) 2002; 47(5): Rutten-van Mölken MPMH, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from the Netherlands. PharmacoEconomics 2001; 19 S2: S1-S6 Oostenbrink JB, Rutten-van Mölken MPMH, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension; a one-year study based on 5

6 retrospective chart review in the Netherlands. Journal of Glaucoma 2001; 10: Feenstra TL, Van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten-van Mölken MPMH. The impact of aging and smoking on the future burden of COPD: A model analysis in the Netherlands. Americal Journal of Respiratory and Critical Care Medicine 2001; 164: Decramer M, Richard Dekhuijzen PN, Van Herwaarden C, Rutten-van Mölken MPMH, Van Schayck CP, Olivieri C, Lankhorst I, Ardia A and the BRONCUS-trial Committee. The bronchitis randomised on NAC cost-utility study (BRONCUS): Hypothesis and design. European Respiratory Journal 2001: 17: Van den Boom G, Rutten-van Mölken MPMH, Molema J, Tirimanne PRS, Van Weel C, Van Schayck CP. The cost-effectiveness of early treatment with fluticasone propionate 250 mcg twice daily in subjects with obstructive airway disease. Results of the DIMCA programme. American Journal of Respiratory and Critical Care Medicine 2001; 164: Goossens MEJB, Rutten-van Mölken MPMH, Vlaeyen JWS, Van der Linden SMJP. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. Journal of Clinical Epidemiology 2000; 53: Oostenbrink JB, Rutten-van Mölken MPMH, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands; an observational study of costs and initial treatment success based on retrospective chart review. Documenta Opthalmologica 2000; 98: Van den Boom G, Rutten-van Mölken MPMH, Folgering H, Van Weel C, Van Schayck CP. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Preventive Medicine 2000; 30: Rutten-van Mölken MPMH. Respiratory questionnaires in COPD. Reply to a letter to the editor by Williams et al., Thorax 2000; 55: 441 Rutten-van Mölken MPMH, Roos B, Van Noord JA. An empirical comparison of the St Georges Respiratory Questionnaire and the Chronic Respiratory Questionnaire in a clinical trial setting. Thorax 1999; 54: Rutten-van Mölken MPMH, Postma MJ, Joore MA, Van Genugten M, Leidl R, Jager JC. Current and future health care impact of asthma and COPD in The Netherlands. Respiratory Medicine 1999; 93: Van der Woude T, Rutten-van Mölken MPMH, Buller HR, Brandjes DPM. Rentabilité de l'utilisation a titre prophylactique des bas de compression chez des patients presentant une thrombose veineuse profonde (The cost-effectiveness of the prophylactic uses of compression stockings in patients with deep-vein thrombosis) Phlébologie 1999; 52(2): Goossens MEJB, Evers S.M.A.A., Vlaeyen JWS, Rutten-van Mölken MPMH, Van der Linden SMJP. Principles of economic evaluation for interventions of chronic musculoskeletal pain. European Journal of Pain 1999 Dec; 3(4):

7 Goossens MEJB, Vlaeyen JWS, Rutten-van Mölken MPMH, Van der Linden SMJP. Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 1999; Kole-Snijders AMJ, Vlaeyen JWS, Goossens MEJB, Rutten-van Mölken MPMH, Heuts PHTG, Van Breukelen G, Van Eek H. Chronic low back pain: what does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial. Journal of Consulting and Clinical Psychology 1999; 67: Rutten-van Mölken MPMH, Van Doorslaer EKA, Till MD. International cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. PharmacoEconomics 1998; 14(6): Van den Boom G, Rutten-van Mölken MPMH, Tirimanna PRS, Van Schayck CP, Van Weel C, Folgering H. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 1998; 11: Van den Boom G, Van Schayck CP, Rutten-van Mölken MPMH, Tirimanna PRS, Den Otter JJ, Van Grunsven PM, Buitendijk MJ, Van Herwaarden CLA, Van Weel C. Active detection of copd and asthma in the general population: results and economic consequences of the DIMCA programme. American Journal of Respiratory and Critical Care Medicine 1998; 158(6): Goossens MEJB, Rutten-van Mölken MPMH, Kohl A, Vlaeyen J, Leidl R. Costeffectiveness of cognitive therapy for chronic low back pain. Health Economics 1998; 7: Hood S, Annemans L, Rutten-van Mölken M. A short-term cost-effectiveness model for oral antidiabetic medicines in Europe. PharmacoEconomics 1998; 13: Rutten-van Mölken M. The cost of asthma and cost-effectiveness of inhaled corticosteroids. Eur Respir Rev 1997; 7: 49, Rutten-van Mölken MPMH, Kerstjens HAM. Combination of inhaled corticosteroids and beta agonists in asthma: clinical and economic implications. Clinical Immunotherapeutics 1996; 6: Rutten-van Mölken MPMH, Kerstjens HAM. Reaction to letter to the editor on Costs and effects of inhaled corticosteroid and bronchodilators in asthma and copd by dr. A. Marabini and A. Siracusa. Am J Respir Crit Care Med 1996 Vlaeyen JWS, Teeken-Gruben NJG, Goossens EJB, Rutten-van Mölken MPMH, Pelt RAGB, Van Eek H, Heuts HTG. Cognitive-educational treatment of fibromyalgia, a randomized clinical trial. Part I: Clinical Effects. Journal of Rheumatology 1996; 23: Goossens MEJB, Rutten-van Mölken MPMH, Leidl R, Bos S, Vlaeyen J, Teeken-Gruben N. Cognitive-educational treatment of fibromyalgia, a randomized clinical trial. Part II: Economic Evaluation. Journal of Rheumatology 1996; 23: Rutten-van Mölken MPMH, Van Doorslaer EKA, Jansen CCM, Kerstjens HAM, Rutten FFH, Cost-effectiveness of inhaled corticosteroid and bronchodilator therapy in asthma and 7

8 COPD. American Review of Respiratory and Critical Care Medicine 151: , 1995 Rutten-van Mölken MPMH, Custers F, Van Doorslaer EKA, Jansen CCM, Heurman L, Smeets SJ, Maesen FPV. Comparing the performance of four different instruments in evaluating the effects of salmeterol on asthma quality of life. European Respiratory Journal 8: , 1995 Rutten-van Mölken MPMH, Bakker CH, Van Doorslaer EKA, Van der Linden Sj. Methodological Issues of Patient Utility Measurement: Experience from two clinical trials. Medical Care 33: , 1995 Van Schayck CP, Rutten MPMH, Van den Boom G, et al., Longfunctie en ervaren gezondheid bij patiënten met astma of chronische obstructieve longziekten in longitudinaal onderzoek. Huisarts en Wetenschap 38: , 1995 Van Schayck CP, Dompeling E, Rutten MPMH, Folgering H, Van den Boom G, Van Weel C, The influence of an inhaled corticosteroid on quality of life in patients with asthma or COPD. Chest 107: , 1995 Bakker CH, Rutten-van Mölken MPMH, Van Doorslaer EKA, Bennett K, Van der Linden Sj. Patient Utilities in Fibromyalgia and the Association with Other Outcome Measures. The Journal of Rheumatology 22: , 1995 Teeken-Gruben NJG, Vlaeyen JWS, Goossens MEJB, Rutten-van Mölken MPMH, Van Eek H, Pelt RAGB, Heuts PHTG. Effectiviteit van een cognitief-educatief behandelingsprogramma voor mensen met het fibromyalgie syndroom. Gedrag en Gezondheid 1995; 23: Rutten-van Mölken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics 1994; 3: Bakker CH, Rutten-van Mölken MPMH, Van Doorslaer EKA, Bennett K, Van der Linden Sj, Feasibility of utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. The Journal of Rheumatology 21: , 1994 Bakker CH, Rutten-van Mölken MPMH, Hidding A, Van Doorslaer EKA, Bennett K, Van der Linden Sj. Patient Utilities in Ankylosing Spondylitis and the Association with Other Outcome Measures. The Journal of Rheumatology 21: , 1994 Rutten-van Mölken MPMH, Van Doorslaer EKA, Jansen CCM, Van Essen-Zandvliet EE, Rutten FFH, Cost-effectiveness of inhaled corticosteroid and bronchodilator therapy in asthmatic children. PharmacoEconomics 4: , 1993 Bakker CH, Rutten-van Mölken MPMH, Van Doorslaer EKA, Bennett K, Van der Linden Sj, Health related utility measurement in patients with ankylosing spondylitis or fibromyalgia. Patient Education and Counseling 20: , 1993 Rutten-van Mölken MPMH, Van Doorslaer EKA, Rutten FFH. Economic appraisal of asthma and COPD care: a literature review Soc Sci Med 35: , 1992 Van Schayck CP, Rutten MPMH, Van Doorslaer EKA, Folgering HF, Van Weel C, Twoyear Bronchodilator Treatment in Patients with Mild Airflow Obstruction. Contradictory 8

9 Effects on Lung Function and Quality of Life. Chest 102: , 1992 Books and book chapters Rutten-van Mölken MPMH, Uyl-de Groot C, Rutten FFH. (eds.) Van kosten tot effecten. Een handleiding voor economische evaluatiestudies in de gezondheidszorg. Tweede, herziene druk (verschijnt in augustus 2010) Rutten-van Mölken MPMH, Feenstra T. The health and economic consequences of smoking and smoking cessation interventions: the Dutch perspective. In: Preedy VR, Watson RR (eds). Handbook of disease burdens and quality of life measures. New York, Springer, 2010, pp Rutten-van Mölken MPMH, Van Busschbach JJ, Rutten FFH (eds). Van kosten tot effecten. Een handleiding voor evaluatiestudies in de gezondheidszorg. ISBN: Elsevier Gezondheidszorg, Maarssen 2000 Rutten-van Mölken MPMH. Health State Preference Estimation in Asthma. In: Weiss KB, Buist AS, Sullivan SD (eds). Asthma's Impact on Society. The social and economic burden. Marcel Dekker, Inc. New York, Basel, 2000 Rutten-van Mölken MPMH, Vleugels A. Hoofdstuk 5: Economische evaluatie (pag ). In: Demedts M, Dijkman JH, Hilvering C, Postma D (eds.) Longziekten. Universitaire Pers Leuven, 4e herziene druk, Van Gorcum, Assen, 1999 Van den Boom G, Rutten-van Mölken MPMH. Economische aspecten. In: Van Schayck CP, Wesseling GJ (eds.) Behandelingsstrategieën bij astma. Pg Bohn Stafleu Van Loghum, Houten, 1999 Rutten-van Mölken MPMH. Costs and Effects of Pharmacotherapy in Asthma and COPD. Ph.D. Dissertation. University Press Maastricht, 1994 Reports and other publications: Goossens L, Knoester P, Rutten-van Mölken MPMH, Avastin, Macugen en Lucentis: vergelijking van medicatiekosten. Pharmaceutisch Weekblad Rutten-van Mölken MPMH, Van Nooten FE. Cost-Consequence Analysis of N-acetylcysteine compared to placebo in patients with moderate or severe COPD: Results from the BRONCUS trial. IMTA report, Rotterdam, July 2004, report number Rutten-van Mölken MPMH. De toekomstige ziektelast van COPD. Patient Care 2003; 30(7): Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MPMH, Cost- Effectiveness Analysis of Face-to-Face Smoking Cessation Interventions by Professionals. IMTA report, Rotterdam, November 2003, reportnumber

10 Hoogendoorn M, Feenstra T, Hoogenveen R, Van Genugten M, Rutten-van Mölken M. A Health Policy Model for COPD: Effects of Smoking Cessation. IMTA report, Rotterdam, December 2003, reportnumber Oostenbrink JB, Rutten-van Mölken MPMH. One-year prospective cost-effectiveness analysis of tiotropium compared to ipratropium for the treatment of COPD in the Netherlands and Belgium. Institute for Medical Technology Assessment, Erasmus University Rotterdam, October 2000 De Witte LP, Dijks B, Gelderblom GJ, Goossens M, Van 's Hoofd W, Van der Pijl DJP, Rutten-van Mölken MPMH, Van Soest K, Tilli D, Wessels R. Manus: een helpende hand. Een verkennende studie naar doelgroepen, indicatiecriteria, gebruik en aspecten van kosteneffectiviteit van de MANUS robotarm. Instituut voor Revalidatievraagstukken, Hoensbroek, 2000 Rutten-van Mölken MPMH. Principles of cost-effectiveness analysis in rheumatology. Rheumatology in Europe 1998; 27/1: 7-10 Van der Woude T, Rutten-van Mölken MPMH. De kosten van veneuze aandoeningen en de kosten-effectiviteit van compressietherapie. IMTA report nr Erasmus University Rotterdam, 1997 Rutten-van Mölken MPMH, Van der Woude T, Wiggers CCMC, Sliggers M. De huidige en toekomstige organisatie van klinisch genetisch onderzoek in Nederland. IMTA report nr Erasmus University Rotterdam, 1998 Rutten-van Mölken M. Onderzoek naar de kosten-effectiviteit van geneesmiddelen: inhalatiecorticosteroïden bij CARA. Health Management Forum 1(2): 21-23, 1995 Teeken-Gruben NJG, Goossens MEJB, Nooyen-Haazen IWCJ, Vlaeyen JWS, Rutten-van Mölken MPMH. Tertiaire preventie van chronische pijn in het houdings- en bewegingsapparaat: het effect van een gecombineerd educatief programma en een cognitieve behandeling. Een kosten-effectiviteitsstudie bij mensen met het fibromyalgiesyndroom. Eindrapport voor het Preaventiefonds (project ). Hoensbroek, februari 1995 Rutten-van Mölken MPMH. Quality of life measurement in pharmaceutical drug trials: basic concepts. In: Ament A. and Evers S. (eds.) Economic Evaluation of Health Care Interventions. Working-paper no , page 43-58, University of Limburg, 1993 Rutten-Van Mölken MPMH, Van Doorslaer EKA, Jansen CCM, Rutten FFH, Kerstjens HAM, Kosten-effectiviteit van farmacotherapie bij CARA-patiënten. Pulmoscript 3: 50-53, 1992 Rutten-van Mölken MPMH, Kwaliteit van leven. Een bruikbaar concept. Medisch Contact 24: , 1992 Rutten M, Vondeling H. Economische evaluatie in het kader van ontwikkelingsgeneeskunde: een algemene inleiding voor artsen. Working-paper nr , Rijksuniversiteit Limburg, Maastricht, 1992 Essink-Bot ML, Rutten-van Mölken MPMH, Het meten van de gezondheidstoestand. IMG/IMTA Erasmus Universiteit Rotterdam/Rijksuniversiteit Limburg ISBN ,

11 Van Mölken MPMH, Van Doorslaer EKA, Rutten FFH. CARA in Cijfers. Verslag van een 'costof-illness' studie. R.U. Limburg, Maastricht,

PUBLIC SUMMARY DOCUMENT

PUBLIC SUMMARY DOCUMENT PUBLIC SUMMARY DOCUMENT Product: Budesonide with eformoterol fumarate dihydrate, powder for oral inhalation, fixed dose combination, 400 micrograms-12 micrograms per dose, Symbicort Turbuhaler 400/12 Sponsor:

More information

SAFE BUT SORRY. Theory, assesment, and treatment of pain-related fear in chronic low back pain patients

SAFE BUT SORRY. Theory, assesment, and treatment of pain-related fear in chronic low back pain patients SAFE BUT SORRY Theory, assesment, and treatment of pain-related fear in chronic low back pain patients SAFE but SORRY: Theory, assessment, and treatment of pain-related fear in chronic low back pain patients

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium salmeterol/fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler ) No. (450/08) GlaxoSmithKline 11 February 2008 The Scottish Medicines Consortium has completed its

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Determinants of Spirometry Use and Accuracy of COPD Diagnosis in Primary Care

Determinants of Spirometry Use and Accuracy of COPD Diagnosis in Primary Care MS #10217r1 Determinants of Spirometry Use and Accuracy of COPD Diagnosis in Primary Care Running title: Spirometry and COPD in primary care Min J Joo MD MPH 1,2, David H Au MD MS 3,4, Marian L Fitzgibbon

More information

Economic impact of COPD

Economic impact of COPD Economic impact of COPD Empirical and model-based studies on the cost-effectiveness of treatment options Martine Hoogendoorn Economic impact of COPD Empirical and model-based studies on the cost-effectiveness

More information

Neck Pain & Cervicogenic Headache Integrating Research into Practice: San Luis Sports Therapy s Approach to Evidence-Based Practice

Neck Pain & Cervicogenic Headache Integrating Research into Practice: San Luis Sports Therapy s Approach to Evidence-Based Practice Neck Pain & Cervicogenic Headache Integrating Research into Practice: San Luis Sports Therapy s Approach to Evidence-Based Practice PROBLEM: Neck Pain and Cervicogenic Headache 66% Proportion of individuals

More information

Current consensus guidelines, such as the Global. Office Spirometry Significantly Improves Early Detection of COPD in General Practice*

Current consensus guidelines, such as the Global. Office Spirometry Significantly Improves Early Detection of COPD in General Practice* Office Spirometry Significantly Improves Early Detection of COPD in General Practice* The DIDASCO Study Johan Buffels, MD; Jan Degryse, MD, PhD; Jan Heyrman, MD, PhD; and Marc Decramer, MD, PhD Study objectives:

More information

2008 New Jersey Academy of Family Physicians

2008 New Jersey Academy of Family Physicians Chronic Obstructive Pulmonary Disease: Using Spirometry to Diagnose COPD in the Family Physician Office An evidence-based CME program developed by the New Jersey Academy of Family Physicians 2008 New Jersey

More information

Indacaterol (Onbrez)

Indacaterol (Onbrez) 1 for chronic obstructive pulmonary disease (IN-da-CAT-er-ol) A once-daily beta 2 -agonist for chronic obstructive pulmonary disease Key points Once-daily dosing provides symptomatic relief in COPD Indacaterol

More information

Bronchodilators in COPD

Bronchodilators in COPD TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for

More information

Drugs Used in Asthma and COPD

Drugs Used in Asthma and COPD Drugs Used in Asthma and COPD Charts 1 and 2 show trends in prescribing for asthma and chronic obstructive pulmonary disease (COPD). Although the recorded prevalence of asthma is higher (5.4% of registered

More information

New inhaled drugs for asthma & COPD: integration into UK practice

New inhaled drugs for asthma & COPD: integration into UK practice New inhaled drugs for asthma & COPD: integration into UK practice Hasanin Khachi Lead Pharmacist - Respiratory Medicine Joint Chair UKCPA Respiratory Group Barts Health NHS Trust 30 th September 2014 Outline

More information

Confirming Diagnosis Through Spirometry

Confirming Diagnosis Through Spirometry Confirming Diagnosis Through Spirometry Shirley F. Jones, M.D., FCCP I have no conflicts of interest Instructional Objectives At the end of this session, learners will be able to: Select individual patients

More information

Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids [ID872]

Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids [ID872] For public handouts Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids [ID872] 1 st Appraisal Committee meeting Clinical Effectiveness and

More information

Topic: New Treatment = Better Outcome?

Topic: New Treatment = Better Outcome? Session on COPD: Novel Concepts and Promising New Drugs Topic: New Treatment = Better Outcome? Through a CME Grant sponsored by New Treatment = Better Outcome? Tim S. Trinidad, MD Disclosure Present: COPD

More information

Acute Care of COPD: Gaps in our knowledge. Robert A. Wise, M.D. May 20, 2010

Acute Care of COPD: Gaps in our knowledge. Robert A. Wise, M.D. May 20, 2010 Acute Care of COPD: Gaps in our knowledge Robert A. Wise, M.D. May 20, 2010 Outline of talk Importance of COPD exacerbations Current treatments Areas for improvement Significant knowledge gaps Strategies

More information

Asthma and COPD. Trends in Prescribing of Drugs for Asthma and COPD in General Practice in England (Chart 1)

Asthma and COPD. Trends in Prescribing of Drugs for Asthma and COPD in General Practice in England (Chart 1) Asthma and COPD This review will focus on the most recent evidence regarding the safety of currently recommended options for treating chronic asthma and exacerbations in chronic obstructive pulmonary disease

More information

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis BACKGROUND Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic and fatal disease characterised by

More information

Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016

Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016 Samer El Rayess, M.D. Internal Medicine, PGY3 29 January 2016 Case Scenario Mr. X., a 50 year old man heavy smoker 80 pack / year known to have -COPD on spiriva at home last exacerbation 9 months ago -Hypertension

More information

Pathway for Diagnosing COPD

Pathway for Diagnosing COPD Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational

More information

Dealing with Differences

Dealing with Differences Dealing with Differences Different populations, data sources and countries in HTA modelling Pepijn Vemer FUNDING: The studies in this thesis were financed by the Dutch Ministry of Health (ch 2), Takeda

More information

ORIGINAL STUDIES. Keywords: Pulmonary rehabilitation; COPD; nutrition

ORIGINAL STUDIES. Keywords: Pulmonary rehabilitation; COPD; nutrition ORIGINAL STUDIES Efficacy and Costs of Nutritional Rehabilitation in Muscle-Wasted Patients With Chronic Obstructive Pulmonary Disease in a Community- Based Setting: A Prespecified Subgroup Analysis of

More information

Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy

Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy 31 st Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy 1 Introduction Chronic obstructive pulmonary disease (COPD) is an important disease for patients, the health

More information

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

More information

Cost-Effectiveness of Physical Therapy and General Practitioner Care for Sciatica

Cost-Effectiveness of Physical Therapy and General Practitioner Care for Sciatica Cost-Effectiveness of Physical Therapy and General Practitioner Care for Sciatica SPINE Volume 32, Number 18, pp 1942 1948 2007, Lippincott Williams & Wilkins, Inc. Pim A. J. Luijsterburg, PhD,* Leida

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations ORIGINAL RESEARCH Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations Kai-Michael Beeh 1 Bettina Hederer 2 Thomas Glaab 2 Achim Müller 2 Maureen

More information

Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology

Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology Introduction Definitions Impact of Exacerbations Assessment of COPD Management of COPD Management of Acute Exacerbations Prevention of Exacerbations COPD

More information

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Development of disability in COPD The decline in airway function may initially go unnoticed as people adapt their lives to avoid

More information

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,

More information

Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain

Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain Article ID: WMC001933 ISSN 2046-1690 Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain Author(s):Ms. Minerva Garcia-fuentes

More information

Chronic Bronchitis. Pamela K. Anderson R. N. 2. Buffalo, NY

Chronic Bronchitis. Pamela K. Anderson R. N. 2. Buffalo, NY Comparison of the Lung Flute with the Acapella in the Treatment of COPD with Chronic Bronchitis Sanjay Sethi, M.D. 1,2 Jane Maloney, R.N. 2 Lori Grove, B.S. 2 Pamela K. Anderson R. N. 2 1 VA WNY Health

More information

28 April 2006 *S000001Q01* 000001 000 DR SAM SAMPLE 999 SAMPLE STREET SAMPLETOWN SAMPLE STATE 9999. Dear Dr Sample, 012282_3_1_LET/000001/000001/i

28 April 2006 *S000001Q01* 000001 000 DR SAM SAMPLE 999 SAMPLE STREET SAMPLETOWN SAMPLE STATE 9999. Dear Dr Sample, 012282_3_1_LET/000001/000001/i 28 April 2006 *S000001Q01* 000001 000 DR SAM SAMPLE 999 SAMPLE STREET SAMPLETOWN SAMPLE STATE 9999 Dear Dr Sample, 012282_3_1_LET/000001/000001/i PPR thirty three Prescribing Practice Review For Primary

More information

SMOKING IN HIV. Michelle Wong Division of Pulmonology, Chris Hani Baragwanath Academic Hospital University of the Witwatersrand

SMOKING IN HIV. Michelle Wong Division of Pulmonology, Chris Hani Baragwanath Academic Hospital University of the Witwatersrand SESSION 16D: LIFESTYLE DISEASES AND HIV SMOKING IN HIV Michelle Wong Division of Pulmonology, Chris Hani Baragwanath Academic Hospital University of the Witwatersrand 15 April 2016 Smoking accounts for

More information

4/12/2010 Update in the management of Asthma and COPD M. Shafick Gareeboo Consultant Chest Physician Consultant Chest 1

4/12/2010 Update in the management of Asthma and COPD M. Shafick Gareeboo Consultant Chest Physician Consultant Chest 1 Update in the management of Asthma and COPD M. Shafick Gareeboo Consultant Chest Physician 1 Content Current guidelines in asthma management Current guidelines in COPD management New treatment for COPD

More information

SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Diagnosis and diagnostic tools Recommendation 1 Diagnosis of COPD (IV) It is recommended that spirometry should be performed

More information

Impact of symptoms of anxiety and depression on COPD Assessment Test (CAT) scores

Impact of symptoms of anxiety and depression on COPD Assessment Test (CAT) scores ERJ Express. Published on October 10, 2013 as doi: 10.1183/09031936.00163913 Impact of symptoms of anxiety and depression on COPD Assessment Test (CAT) scores Authors Christina W. Hilmarsen* 1, Sarah Wilke*

More information

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation REVIEW CHRONIC OBSTRUCTIVE PULMONARY DISEASE Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation NICHOLAS J. GROSS, MD, PHD Chronic

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

Role of dual bronchodilation in COPD

Role of dual bronchodilation in COPD Role of dual bronchodilation in COPD Canadian Respiratory Conference, Calgary, May 25 th, 2014 François Maltais Centre de Pneumologie IUCPQ Québec. Canada Disclosure Speaker bureau: Boehringer Ingelheim,

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

National Learning Objectives for COPD Educators

National Learning Objectives for COPD Educators National Learning Objectives for COPD Educators National Learning Objectives for COPD Educators The COPD Educator will be able to achieve the following objectives. Performance objectives, denoted by the

More information

Service Specification

Service Specification Service Specification Spirometry in Primary Care Date: February 2011 Document Reference: Service Specification (V4.0) Contents: Section Page 1 Definition of service 3 2 Training 4 3 Reporting / Monitoring

More information

Persistence with inhaled corticosteroid therapy in daily practice

Persistence with inhaled corticosteroid therapy in daily practice Respiratory Medicine (2004) 98, 752 759 Persistence with inhaled corticosteroid therapy in daily practice N.S. Breekveldt-Postma a, *, C.M.J.M. Gerrits b, J.W.J. Lammers c, J.A.M. Raaijmakers b,d, R.M.C.

More information

Update in ASTHMA: Clearing the Air What Works and What Doesn t? Blair Brooks MD Dartmouth Hitchcock Medical Center COOP Meeting Pre Workshop 2/04/05

Update in ASTHMA: Clearing the Air What Works and What Doesn t? Blair Brooks MD Dartmouth Hitchcock Medical Center COOP Meeting Pre Workshop 2/04/05 Update in ASTHMA: Clearing the Air What Works and What Doesn t? Blair Brooks MD Dartmouth Hitchcock Medical Center COOP Meeting Pre Workshop 2/04/05 Knowing is not enough: we must apply. Willing is not

More information

ONCE-DAILY TIOTROPIUM RESPIMAT ADD-ON TO ICS ± LABA IMPROVES CONTROL ACROSS ASTHMA SEVERITIES

ONCE-DAILY TIOTROPIUM RESPIMAT ADD-ON TO ICS ± LABA IMPROVES CONTROL ACROSS ASTHMA SEVERITIES SPIRIVA Respimat is approved for use in asthma in the EU, Japan, the USA and many other countries. The label varies by country. Please refer to the local product information ONCE-DAILY TIOTROPIUM RESPIMAT

More information

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life Eur Respir J, 1995, 8, 888 898 DOI: 10.1183/09031936.95.08060888 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Comparison of performance

More information

http://ha-ring.nl/en/tool-10

http://ha-ring.nl/en/tool-10 Page 1 of 5 Knowledge base guideline development Materials to support guideline development Tool for implementation of guidelines Contents 1. Introduction 2. Objective of this tool 3. Content of the tool

More information

Clinical Practice Guideline for the Management of Asthma in Children and Adults

Clinical Practice Guideline for the Management of Asthma in Children and Adults Clinical Practice Guideline for the Management of Asthma in Children and Adults Assessment: A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function

More information

Inhaled Corticosteroids and the Risk of Mortality and Readmission In Elderly Patients with Chronic Obstructive Pulmonary Disease

Inhaled Corticosteroids and the Risk of Mortality and Readmission In Elderly Patients with Chronic Obstructive Pulmonary Disease Inhaled Corticosteroids and the Risk of and In Elderly Patients with Chronic Obstructive Pulmonary Disease DON D. SIN and JACK V. TU The Institute for Clinical Evaluative Sciences (ICES) and The Department

More information

Asthma in Older Adults: overcoming the challenges of diagnosis and management

Asthma in Older Adults: overcoming the challenges of diagnosis and management Asthma in Older Adults: overcoming the challenges of diagnosis and management Jennifer Gonzalez McComb, MD, MPH, FACP Section Chief, Pulmonary and Critical Care Medicine UPMC Shadyside Hospital April 9,

More information

Claudia M. Witt, MD, MBA

Claudia M. Witt, MD, MBA Costs and cost-effectiveness of Complementary and Alternative Medicine Complementary and Alternative Medicine Innovation and Added Value for European Healthcare 9 October 2012 European Parliament, Brussels

More information

Physical therapy for patients dying at home of chronic obstructive pulmonary disease A Qualitative Study

Physical therapy for patients dying at home of chronic obstructive pulmonary disease A Qualitative Study Physical therapy for patients dying at home of chronic obstructive pulmonary disease A Qualitative Study D.M. Keesenberg, Pt, student Science for physical therapy Physical therapy practice Zwanenzijde,

More information

Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study

Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study Bartolomé R. Celli 1, Nicola E. Thomas 2, Julie A. Anderson 2, Gary T.

More information

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Harvard Vanguard Medical Associates Case Study Organization Profile Founded in the 1960s, Harvard Vanguard Medical

More information

Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans op longkanker dan rokers

Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans op longkanker dan rokers Academisch centrum huisartsgeneeskunde Pneumologie Juni 2012 Prof W Janssens Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans

More information

Do Chiropractic Physician Services for Treatment of Low Back and Neck Pain Improve the Value of Health Benefit Plans?

Do Chiropractic Physician Services for Treatment of Low Back and Neck Pain Improve the Value of Health Benefit Plans? Do Chiropractic Physician Services for Treatment of Low Back and Neck Pain Improve the Value of Health Benefit Plans? An Evidence-Based Assessment of Incremental Impact on Population Health and Total Health

More information

Inside. Managing COPD and preventing progression. Diagnose early and identify those at risk

Inside. Managing COPD and preventing progression. Diagnose early and identify those at risk Managing COPD and preventing progression Chronic obstructive pulmonary disease (COPD) caused over 5000 deaths in Australia in 2003. 1 About one-third of people with the disease reported severe disability

More information

COPD and Asthma Management. Allison Nykolaychuk,, RRT, FCSRT Education Coordinator Respiratory Therapy Zone 2, Horizon Health Network

COPD and Asthma Management. Allison Nykolaychuk,, RRT, FCSRT Education Coordinator Respiratory Therapy Zone 2, Horizon Health Network COPD and Asthma Management Allison Nykolaychuk,, RRT, FCSRT Education Coordinator Respiratory Therapy Zone 2, Horizon Health Network What are we talking about? Asthma Definition: Consider when symptoms

More information

CURRICULUM VITAE KIRK GEORGE VOELKER, M.D.

CURRICULUM VITAE KIRK GEORGE VOELKER, M.D. PERSONAL INFORMATION DATE OF BIRTH December 29, 1961 PLACE OF BIRTH OFFICE ADDRESS E-MAIL Buffalo, NY. 1537 State St. 34236 (941) 330-1696 Dr.Voelker@comcast.net ACADEMIC RECORD UNDERGRADUATE MEDICAL SCHOOL

More information

Update in ASTHMA and COPD: Clearing the Air What Works and What Doesn t?

Update in ASTHMA and COPD: Clearing the Air What Works and What Doesn t? Update in ASTHMA and COPD: Clearing the Air What Works and What Doesn t? Blair Brooks MD Dartmouth Hitchcock Medical Center Community Faculty Development Symposium 11/05/04 Knowing is not enough: we must

More information

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575 EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma

More information

Which smokers develop COPD? A prediction rule. Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW

Which smokers develop COPD? A prediction rule. Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW 5 Which smokers develop COPD? A prediction rule Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW 54 Prediction of moderate COPD Introduction Tobacco smoking is the main risk factor for

More information

1-844-FAX-A For more information, call Access 360 at ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET.

1-844-FAX-A For more information, call Access 360 at ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET. 1-844-ASK-A360 1-844-275-2360 1-844-FAX-A360 1-844-329-2360 www.myaccess360.com For more information, call Access 360 at 1-844-ASK-A360, Monday through Friday, 8:00 AM to 8:00 PM ET. SYMBICORT is indicated

More information

Asthma POEMs. Patient Orientated Evidence that Matters

Asthma POEMs. Patient Orientated Evidence that Matters ASTHMA POEMs Asthma POEMs Patient Orientated Evidence that Matters Developed by the Best Practice Advocacy Centre Level 8, 10 George Street PO Box 6032 Dunedin Phone 03 4775418 Fax 03 4772622 Acknowledgement

More information

Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations

Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations Data presented from the publication: M. de Wit, et al. Ann Rheum Dis. 2011;70:891-5. Epub Apr 7, 2011.

More information

THE USE OF SOCIETAL CRITERIA IN PRIORITY SETTING FOR HEALTH TECHNOLOGY ASSESSMENT IN THE NETHERLANDS

THE USE OF SOCIETAL CRITERIA IN PRIORITY SETTING FOR HEALTH TECHNOLOGY ASSESSMENT IN THE NETHERLANDS International Journal of Technology Assessment in Hearth Care, 14:2 (1998), 226-236. Copyright 1998 Cambridge University Press. Printed in the U.S.A. THE USE OF SOCIETAL CRITERIA IN PRIORITY SETTING FOR

More information

Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD

Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD BARCELONA, July 7th: Laboratorios Almirall, S.A. and Forest Laboratories, Inc. (NYSE: FRX) have announced that

More information

Anne Lindberg, MD; Ann-Christin Jonsson, SRN; Eva Rönmark, PhD; Rune Lundgren, MD, PhD, FCCP; Lars-Gunnar Larsson, MD, PhD; and Bo Lundbäck, MD, PhD

Anne Lindberg, MD; Ann-Christin Jonsson, SRN; Eva Rönmark, PhD; Rune Lundgren, MD, PhD, FCCP; Lars-Gunnar Larsson, MD, PhD; and Bo Lundbäck, MD, PhD 10 y Anne Lindberg, MD; Ann-Christin Jonsson, SRN; Eva Rönmark, PhD; Rune Lundgren, MD, PhD, FCCP; Lars-Gunnar Larsson, MD, PhD; and Bo Lundbäck, MD, PhD (BTS) (GOLD) (GOLD 0 ) 10 y 1986 6 610 8 3 1 1919

More information

Medications for COPD: A Review of Effectiveness

Medications for COPD: A Review of Effectiveness Medications for COPD: A Review of Effectiveness GIL C. GRIMES, MD; JOHN L. MANNING, MD; PARITA PATEL, MD; and R. MARC VIA, MD Texas A&M University Health Science Center, Temple, Texas Chronic obstructive

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons

Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons 4813 Workshop: Stepping Down Asthma MedicaDons: Benefits and Risks Monday March 3, 2014 4:45 pm to 6:00 pm AAAAI 2014 John B. Hagan,

More information

Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey

Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey Chapter 4 Physical therapy in rheumatoid arthritis: results of a national survey E.J. Hurkmans L.C. Li J. Verhoef T.P.M. Vliet Vlieland Musckuloskeletal Care [in press] Chapter 4 Abstract Background and

More information

Improving Chronic Care

Improving Chronic Care Improving Chronic Care Developing and testing disease-management interventions applied in COPD care Karin Lemmens Funding The research project was supported by an unrestricted grant from PICASSO for COPD,

More information

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment

Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment A WHITE PAPER BY Disease Therapy Management (DTM) Enhances Rheumatoid Arthritis Treatment Increased adherence rates deliver improved outcomes for patients FALL 2010 The Benefits of DTM for Rheumatoid Arthritis

More information

Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands 3

Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands 3 This paper presents a summary of the Evidence Review Group report for the single technology appraisal entitled Roflumilast for the management of severe chronic obstructive pulmonary disease Riemsma R,

More information

Thanks to the National Board of Chiropractic Examiners for permission to reproduce these abstracts.

Thanks to the National Board of Chiropractic Examiners for permission to reproduce these abstracts. Thanks to the National Board of Chiropractic Examiners for permission to reproduce these abstracts. The Effectiveness of Chiropractic Care A substantial number of systematic reviews of literature and meta-analyses

More information

SmPC SYMBICORT pressurised inhalation, suspension Approved indications and posology given in Section 4. CLINICAL PARTICULARS

SmPC SYMBICORT pressurised inhalation, suspension Approved indications and posology given in Section 4. CLINICAL PARTICULARS Table VI-14 Risk miminisation by safety concern: off-label use of SYMBICORT pressurised inhalation, suspension for the treatment of asthma, in children, adolescents, or adults Safety concern Routine risk

More information

Chronic obstructive pulmon -

Chronic obstructive pulmon - Don D. Sin, MD, MPH, FRCPC Pharmacological management of stable chronic obstructive pulmonary disease Once the severity of a patient s COPD has been quantified by spirometry, appropriate agents including

More information

FRESH AIR UGANDA SURVEY ON THE PREVALENCE AND BURDEN OF COPD AND ITS RISK FACTORS IN A RURAL AREA OF UGANDA

FRESH AIR UGANDA SURVEY ON THE PREVALENCE AND BURDEN OF COPD AND ITS RISK FACTORS IN A RURAL AREA OF UGANDA 1 FRESH AIR UGANDA SURVEY ON THE PREVALENCE AND BURDEN OF COPD AND ITS RISK FACTORS IN A RURAL AREA OF UGANDA Frederik van Gemert, general practitioner and researcher University Medical Centre Groningen,

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Progress in Treating Disease: The Case of Asthma

Progress in Treating Disease: The Case of Asthma 13TH EUROPEAN HEALTH FORUM CHRONIC RESPIRATORY DISEASES: A NEGLECTED EPIDEMICS GASTEIN 7 OCTOBER 2010 Progress in Treating Disease: The Case of Asthma Leonardo M. Fabbri Clinica di Malattie dell Apparato

More information

Value of Homecare: COPD and Long-Term Oxygen Therapy. A White Paper

Value of Homecare: COPD and Long-Term Oxygen Therapy. A White Paper Value of Homecare: COPD and Long-Term Oxygen Therapy A White Paper Chronic Obstructive Pulmonary Disease (COPD) is the 4 th leading cause of death in the world and afflicts over 14 million Americans. The

More information

medicineupdate to find out more about this medicine

medicineupdate to find out more about this medicine medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition

More information

Dec 2016 Jan Feb Your life, your choice, your health! h e a l t hy C A M R O S E L I V I N G C E N T R E

Dec 2016 Jan Feb Your life, your choice, your health! h e a l t hy C A M R O S E L I V I N G C E N T R E Dec 2016 Jan Feb 2017 Your life, your choice, your health! C A M R O S E h e a l t hy L I V I N G C E N T R E INDEX OF CLASSES OFFERED NAME OF CLASS PAGE NAME OF CLASS PAGE Chronic Disease Management NUMBER

More information

Using ÖMPQ to Reduce Risk of Prolonged Disability in Workers Compensation Cases

Using ÖMPQ to Reduce Risk of Prolonged Disability in Workers Compensation Cases Using ÖMPQ to Reduce Risk of Prolonged Disability in Workers Compensation Cases International Forum on Disability Management Section: Mental Health September 21, 2010 Dr. Douglas Margison, Chief Medical

More information

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.

More information

Publications. Paper presentations

Publications. Paper presentations PROFESSIONAL BIOGRAPHY Paul Wimmers started his career as a Technical Engineer and Instructor and made a career change in 1998 to pursue his interests in psychology and education. He received his Master

More information

Scottish Medicines Consortium. erdosteine 300mg capsules (Erdotin ) No. (415/07) Edmond Pharma Sr.l/Galen Ltd. 5 October 2007

Scottish Medicines Consortium. erdosteine 300mg capsules (Erdotin ) No. (415/07) Edmond Pharma Sr.l/Galen Ltd. 5 October 2007 Scottish Medicines Consortium erdosteine 300mg capsules (Erdotin ) No. (415/07) Edmond Pharma Sr.l/Galen Ltd. 5 October 2007 The Scottish Medicines Consortium has completed its assessment of the above

More information

Avery strong evidence base supports the

Avery strong evidence base supports the THE EVOLVING ROLE OF REHABILITATION IN COPD * Andrew L. Ries, MD, MPH ABSTRACT A strong, growing, scientifically sound evidence base supports the benefits of pulmonary rehabilitation for patients with

More information

Is it safe to use long acting β agonists in asthma and chronic obstructive pulmonary disease? Implications of recent trials and meta analyses

Is it safe to use long acting β agonists in asthma and chronic obstructive pulmonary disease? Implications of recent trials and meta analyses Review article Is it safe to use long acting β agonists in asthma and chronic obstructive pulmonary disease? Implications of recent trials and meta analyses Malcolm R. Sears Firestone Institute for Respiratory

More information

A COPD Health Management Program in a Community-Based Primary Care Setting: A Randomized Controlled Trial

A COPD Health Management Program in a Community-Based Primary Care Setting: A Randomized Controlled Trial A COPD Health Program in a Community-Based Primary Care Setting: A Randomized led Trial Peian Lou PhD, Peipei Chen PhD, Pan Zhang MPH, Jiaxi Yu PhD, Yong Wang MD, Na Chen PhD, Li Zhang PhD, Hongmin Wu

More information

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

More information

Wolters Kluwer Lippincott Williams & Wilkins Health Philadelphia Baltimore New York«London Buenos Aires Hong Kong Sydney Tokyo

Wolters Kluwer Lippincott Williams & Wilkins Health Philadelphia Baltimore New York«London Buenos Aires Hong Kong Sydney Tokyo Essentials of Pharmacoeconomics SECOND EDITION Karen L. Rascati, PhD Eckerd/Turley Centennial Professor of Health Outcomes and Pharmacy Practice University of Texas College of Pharmacy Austin, Texas Wolters

More information

GSK Respiratory Committed to a brighter future for people with respiratory disease

GSK Respiratory Committed to a brighter future for people with respiratory disease GSK Respiratory Committed to a brighter future for people with respiratory disease First Mission Improve Alliance Leadership Community Medicines Impact Healthcare Patients Professional Partnerships Initiative

More information

A Mini-Sentinel Assessment of FDA Regulatory Policies for Long Acting Beta 2 Agonists

A Mini-Sentinel Assessment of FDA Regulatory Policies for Long Acting Beta 2 Agonists A Mini-Sentinel Assessment of FDA Regulatory Policies for Long Acting Beta 2 Agonists Melissa Butler, PharmD, MPH, PhD Center for Health Research Southeast Kaiser Permanente Georgia KP Center for Effectiveness

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways

More information